Unknown PHASE3 INTERVENTIONAL 2-arm NCT05908071

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SHEN26 Capsule in Adult Participants With Mild to Moderate COVID-19

Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.

Conditions COVID-19

Interventions SHEN26 capsule SHEN26 placebo

Updated 4 times since 2023 Last updated: Jun 19, 2023 Started: May 13, 2023 Primary completion: May 31, 2024 Completion: Jul 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates COVID-19 and is currently ongoing. Shenzhen Kexing Pharmaceutical Co., Ltd. leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Jun 2025 — Present [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen Kexing Pharmaceutical Co., Ltd.

Data source: Kexing Biopharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China